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Abstract
IMPORTANCE Risk of Alzheimer disease (AD) is particularly high for individuals with Down
syndrome (DS). The ε4 allele of the apolipoprotein E gene (APOE ε4) is associated with an additional
risk for AD. In typical development, there is evidence that the APOE ε4 genotype is associated with
an early cognitive advantage. Here we investigate associations of APOE ε4 with attention across the
life span of individuals with DS.
OBJECTIVE To investigate associations between APOE ε4 and attentional abilities in young children
and in adults with DS.
DESIGN, SETTINGS, AND PARTICIPANTS In this cross-sectional study, data were collected from 80
young children with DS (8-62 months of age) and 240 adults with DS (16-71 years of age) during the
period from 2013 to 2018 at a research center to examine the association between APOE status (ε4
carrier vs ε4 noncarrier) and attentional abilities.
EXPOSURE APOE status (ε4 carrier vs ε4 noncarrier).
MAIN OUTCOMES AND MEASURES For the children, attentional ability was assessed using an
eye-tracking paradigm, the gap-overlap task; the size of the gap effect was the primary outcome. For
the adults, attentional ability was assessed using the CANTAB simple reaction time task; the standard
deviation of response time latencies was the primary outcome. Cross-sectional developmental
trajectories were constructed linking attentional ability with age in ε4 carriers and ε4 noncarriers for
children and adults separately.
RESULTS The child sample comprised 23 ε4 carriers and 57 ε4 noncarriers. The adult sample
comprised 61 ε4 carriers and 179 ε4 noncarriers. For the children, a significant difference between
trajectory intercepts (ηp
2 = 0.14) indicated that ε4 carriers (B = 100.24 [95% CI, 18.52-181.96])
exhibited an attentional advantage over ε4 noncarriers (B = 314.78 [95% CI, 252.17-377.39]). There
was an interaction between APOE status and age (ηp
2 = 0.10); while the gap effect decreased with
age for ε4 noncarriers (B = −4.58 [95% CI, −6.67 to −2.48]), reflecting the development of the
attention system, there was no change across age in ε4 carriers (B = 0.77 [95% CI, −1.57 to 3.12]). For
the adults, there was no main effect of ε4 carrier status, but there was an interaction between APOE
status and age (B = 0.02 [95% CI, 0.004-0.07]), so that ε4 carriers had poorer attentional ability
than ε4 noncarriers at older ages.
CONCLUSIONS AND RELEVANCE APOE ε4 is associated with an attentional advantage early in
development and a disadvantage later in life for individuals with DS, similar to the pattern reported
(continued)
Key Points
Question What are the associations
between the Alzheimer disease risk
allele apolipoprotein E (APOE) ε4 and
attention across the life span of
individuals with Down syndrome?
Findings In a cross-sectional study
including 80 young children and 240
adults with Down syndrome, an
advantage was observed in attention for
ε4 carriers relative to ε4 noncarriers
among young children. Among young
adults, no attentional advantage was
observed in ε4 carriers, and possession
of an ε4 allele was associated with a
disadvantage among older adults.
Meaning Although APOE ε4 is a risk
allele for Alzheimer disease later in life,
it may be associated with an attentional
advantage in the early development of
individuals with Down syndrome.
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Abstract (continued)
in typical development. Understanding the differential role of APOE across the life span is an
important step toward future interventions.
JAMA Network Open. 2020;3(9):e2018221. doi:10.1001/jamanetworkopen.2020.18221
Introduction
Individuals with Down syndrome (DS) show a much higher rate of Alzheimer disease (AD) than the
general population, likely owing to the extra copy of chromosome 21.1 Yet, a large amount of
variability in the clinical presentation and age at onset of AD exists among individuals with DS.2 Some
of this variability may be explained by variation in the apolipoprotein E (APOE) gene on chromosome
19, with the ε4 allele of APOE associated with an increased risk for AD in both the general population
and in individuals with DS.2-4
Even though AD emerges over the last few decades of life, changes associated with the different
alleles of the APOE gene may already be detected in early development.5-7 Some studies of typically
developing individuals suggest that the same ε4 allele that is associated later in life with AD risk may
provide an advantage over other variants of the gene in early development (representing an example
of genetic antagonistic pleiotropy).7,8 However, it is unclear what role APOE plays across the life span
of an individual with DS, given that DS is associated with both intellectual disability in early life and
an ultra-high risk for AD in later life.1
The APOE gene plays a central role in the metabolism of lipids,8 the principal components of
myelin, and myelination is a crucial process in white matter development.5,9 The early development
of white matter pathways has been associated with faster reaction times in an attentional
eye-tracking task, the gap-overlap task.10 The ε4 allele has been associated with higher myelination
levels during infancy but slower myelination across early childhood compared with non-ε4 alleles.5,9
We therefore hypothesized that developmental changes in attentional abilities (as a core cognitive
function that can be measured across the life span) will reflect developmental changes in
myelination, as well as cognitive decline associated with neurodegeneration due to AD in later life.
Methods
Participants
This study was embedded in the London Down Syndrome (LonDownS) Consortium, a large project
aiming to understand the life-span development of individuals with DS. Of 115 younger children and
452 adults with DS, recruited via existing participant databases and support groups,11 genetic and
attentional data were available for 81 children and 243 adults (for more details, see eMethods 1 in the
Supplement). One child and 3 adults carried genotype APOE ε2/ε4, which has an unclear association
with AD risk, and were therefore excluded from further analyses. The final sample consisted of 80
children and 240 adults with DS (Table).
Ethical approval was obtained for all adults and children from the North West Wales National
Health Service Research Ethics Committee and for children from the Birkbeck Psychological Sciences
Ethics Committee. Written informed consent was obtained from the parents of all of the children,
from adults when they had the capacity to consent, and via an appointed consultee when the adults
did not have the capacity to consent, in accordance with the UK Mental Capacity Act 2005.
Participants were given a small gift in return for their participation. The Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) reporting guidelines for cross-sectional studies were
followed.
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Procedure and Materials
APOE genotype was determined using a Thermo Fisher Scientific Taqman assay for single-nucleotide
variations rs7412 and rs429358 from saliva or blood samples.
The gap-overlap task was used to measure attentional ability in children, through assessing the
efficiency of visual orienting.12,13 In this gaze-contingent eye-tracking task (eMethods 2 in the
Supplement), the child was presented with a central stimulus (CS) followed by a peripheral stimulus
(PS). Attentional abilities were probed in 3 conditions which manipulated the timing of these stimuli.
In the baseline condition, CS offset occurred at the same time as PS onset. In the gap condition, CS
offset preceded PS onset by 200 milliseconds. In the overlap condition, the CS remained on screen at
PS onset and for the duration of PS presentation. Attentional abilities were assessed based on the
difference between the saccadic reaction time (SRT) for the overlap and gap conditions, called the
gap effect.14
The simple reaction time task from the Cambridge Neuropsychological Test Automated Battery
(CANTAB) was used to measure attentional ability in adults.15 Participants were required to press a
button as soon as a white square appeared on the computer screen (eMethods 3 in the Supplement).
Response time in this task is dependent on both attentional and motor abilities, with the latter known
to be affected with a high degree of variability in individuals with DS.16 To account for this variability,
the standard deviation (SD) of the response time rather than the response time itself was used as the
measure of attention. This allowed for an estimate of consistency in response time, and thus better
reflected attentional ability than response time itself.16 Floor effects were managed in keeping with
previous studies.2
Table. Characteristics of Participants
Characteristic
Children, No. (%) Adults, No. (%)
Comparison, ε4 carriers vs ε4
noncarriers
P value, ε4 carriers vs ε4
noncarriers
ε4 Carriers ε4 Noncarriers ε4 Carriers ε4 Noncarriers Children Adults Children Adults
No. 23 57 61 179 NA NA NA NA








U = 838.50 U = 4993.50 .05 .32
APOE genotype
ε2/ε2 0 0 0 3 (1.7)
NA NA NA NA
ε2/ε3 0 11 (19.3) 0 34 (19.0)
ε3/ε3 0 46 (80.7) 0 142 (79.3)
ε3/ε4 21 (91.3) 0 58 (95.1) 0
ε4/ε4 2 (8.7) 0 3 (4.9) 0
Sex
Female 11 (47.8) 21 (36.8) 30 (49.2) 84 (46.9)
χ 21 = 0.82 χ 21 = 0.09 .45 .76Male 12 (52.2) 36 (63.2) 31 (50.8) 95 (53.1)
Ethnicitya




test = 2.99 .70 .54
Asian 0 5 (8.8) 0 5 (2.8)
Black 1 (4.3) 3 (5.3) 3 (4.9) 6 (3.4)
Mixed 1 (4.3) 3 (5.3) 3 (4.9) 5 (2.8)
Other 0 1 (1.8) 0 3 (1.7)
Psychotropic
medicationb
0 0 15 (24.6) 31 (17.5)c NA χ 21 = 1.46 NA .23
Abbreviations: APOE, apolipoprotein E; IQR, interquartile range; NA, not applicable.
a The options were defined by the investigators based on the Office for National
Statistics classifications and reported by parents or caregivers. Ethnicity was measured
in this study to ascertain that the demographic characteristics of ε4 carriers and ε4
noncarriers were comparable.
b Psychotropic medication as reported by parents or caregivers was compared across ε4
carriers and ε4 noncarriers because it may be associated with attentional
performance.23
c Report on psychotropic medication missing from 2 ε4 noncarriers in the adult sample.
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Statistical Analysis
General linear models were used to examine the association between APOE ε4 status and attentional
abilities in children and adults with DS. The level of α was set to .05, and all tests were 2-tailed. B
represents the unstandardized coefficients.
Results
The child sample comprised 23 ε4 carriers (28.8%) and 57 ε4 noncarriers (71.3%), and the adult
sample comprised 61 ε4 carriers (25.4%) and 179 ε4 noncarriers (74.6%) (Table). The prevalence of
the APOE ε4 allele in the present study reflects the distribution in the general population.4
Child Sample
The trajectories of the gap effect across age among children with DS who were ε4 carriers and ε4
noncarriers (Figure 1A) were compared using a general linear model estimating the gap effect from
age with APOE group as a between-participants factor. As indicated by a significant difference
between trajectory intercepts (F1,76 = 12.22; P < .001; ηp
2 = 0.14), ε4 carriers (B = 100.24 [95% CI,
18.52-181.96]; P = .02) exhibited an attentional advantage over ε4 noncarriers (B = 314.78 [95% CI,
252.17-377.39]; P < .001). While the gap effect decreased with age among ε4 noncarriers (B = −4.58
[95% CI, −6.67 to −2.48]; P < .001), it did not decrease with age among ε4 carriers (B = 0.77 [95%
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A, Gap effect in ε4 carriers and ε4 noncarriers computed as gap saccadic reaction time (SRT) subtracted from overlap SRT. B, Gap SRT and overlap SRT in ε4 carriers. C, Gap SRT and
overlap SRT in ε4 noncarriers.
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CI, −1.57 to 3.12]; P = .50; interaction of APOE group × age: F1,76 = 8.55; P = .005; ηp
2 = 0.10).
Decompositions of trajectories for the gap condition (oculomotor efficiency) and overlap condition
(attentional disengagement + oculomotor efficiency)10 are shown in Figure 1B and C. While the SRTs
of the ε4 noncarriers decreased more rapidly in the overlap condition (B = −6.05 [95% CI, −8.10 to
−3.99]; P < .001) than in the gap condition (B = −1.47 [95% CI, −2.55 to −0.39]; P = .009)
(F1,55 = 19.10; P < .001; ηp
2 = 0.26), this was not the case for ε4 carriers (gap condition: B = −3.60
[95% CI, −4.99 to −2.22]; P < .001; overlap condition: B = −2.83 [95% CI, −5.68 to 0.01]; P = .05)
(F1,21 = 0.47; P = .50; ηp
2 = 0.02). The slopes were significantly different between the groups in the
gap condition (interaction of APOE group × age: F1,76 = 4.90; P = .03; ηp
2 = 0.06). In the overlap
condition, the groups differed in intercepts (ε4 carriers: B = 516.51 [95% CI, 417.29-615.72]; P < .001;
ε4 noncarriers: B = 669.42 [95% CI, 608.12-730.72]; P < .001) (F1,76 = 6.01; P = .02; ηp
2 = 0.07).
Taken together, these results indicate an early attentional advantage but slower development in ε4
carriers compared with ε4 noncarriers.
Adult Sample
For the larger adult sample, a general linear model was used to estimate simple reaction time latency
SD from age, APOE group, sex, and an APOE group × age interaction term (Figure 2). The regression
model was significant (F4,235 = 28.03; P < .001; R
2 = 0.32). Simple reaction time latency SD increased
with age, but there were no main effects of APOE group or sex (age: B = 0.06 [95% CI, 0.04-0.10];
P < .001; female sex: B = 0.66 [95% CI, −2.17 to 3.76]; P = .74; ε4 carriers: B = −20.04 [95% CI,
−82.64 to 8.44]; P = .15). However, the APOE group × age interaction was significant (B = 0.02 [95%
CI, 0.004-0.07]; P = .03), indicating a faster reduction of attentional abilities in ε4 carriers with
increasing age; performance was poorer in the ε4 carrier group from midlife (Figure 2). A model that
included level of intellectual disability explained more of the variance in adult attentional abilities
but did not alter the pattern of effects of age and its interaction with APOE group (eResults in the
Supplement).
Discussion
To our knowledge, this is the first study showing that the ε4 variant of the APOE gene is associated
with an advantage in early development in individuals with DS, a neutral effect in early adulthood,
and a deleterious effect in late adulthood (Figure 1 and Figure 2). The early advantage is consistent
with a report on typically developing 2-year-olds when ε4 carriers performed better on a
standardized developmental test (the Bayley Scales of Infant Development, Second Edition) than ε4
noncarriers,7 whereas cognitive studies of older children and young adults typically do not show
Figure 2. Adult Sample: Associations Between Cambridge Neuropsychological Test Automated Battery Simple


























20 30 40 50 7060 8010
APOE ε4 carriers
APOE ε4 noncarriers
Linear (APOE ε4 carriers)
Linear (APOE ε4 noncarriers)
Simple reaction time latency standard deviation (SD)
in ε4 carriers and ε4 noncarriers for adult participants.
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differences between ε4 carriers and ε4 noncarriers.17 The poorer attentional abilities observed in late
adulthood in ε4 carriers compared with ε4 noncarriers are likely associated with the increased risk
of AD for ε4 carriers.3
In our child sample, we observed an early attentional advantage but slower development in ε4
carriers compared with ε4 noncarriers. These results are consistent with findings for typical
development that ε4 carriers between 2 and 25 months of age show greater myelination early in
development than ε4 noncarriers but subsequent slower development.5,9 However, the exact nature
of the neural correlates associated with attentional trajectories in early development, and how these
are associated with APOE status, remains to be fully examined. In adults, the visuospatial attentional
orienting system is underpinned by a functional network that includes left and right parietal regions,
and is linked to a larger neural network including frontal eye fields and subcortical areas including the
superior colliculus.18 Frontal and parietal regions have been found to have a higher myelin water
fraction in 2- to 6-month-old ε4 carriers,5 potentially contributing to the early attentional advantage
observed in the present study. Furthermore, in infants and adults, the splenium of the corpus
callosum has been identified as a large white matter region that can be used as a marker of individual
differences in the orienting network and associated attentional performance (particularly on the
overlap trials of the gap-overlap task).10,19 The association between age and myelin water fraction of
the splenium is attenuated in ε4 carriers early in development.5 This is in line with our findings of an
attenuated association between age and the gap effect (likely due to performance on overlap trials
that emphasize attentional disengagement) in ε4 carriers. In later life, even though the splenium of
the corpus callosum may not be the primary area associated with AD, the rate of atrophy of this
region has been found to be associated with the progression of AD severity, possibly owing to a loss
of callosally projecting cortical neurons.20
The increased risk of AD for ε4 carriers is likely associated with the poorer attentional abilities
that we observed in late adulthood in ε4 carriers compared with ε4 noncarriers on the CANTAB
simple reaction time task. Using the same adult sample reported here, this task has been found to be
one of the most sensitive tasks associated with cognitive decline in adults with DS.2 In the present
study, we detected diverging trajectories on this task based on APOE status, consistent with the
onset of AD brain pathology in individuals with DS in their 30s.1 Thus, our results are in line with
findings that the APOE ε4 genotype is associated with an earlier and faster progression of AD.2,3
Taken together, our results could be viewed as the differential effects of APOE ε4 across the life
span (an antagonistic pleiotropic effect). However, it remains unclear how APOE involvement in early
development is mechanistically connected to AD. Several nonmutually exclusive hypotheses have
been advanced for the mechanisms by which APOE ε4 increases risk of AD, based on the role of APOE
in lipid metabolism. These include enhancement of amyloid-β production, modulation of tau
phosphorylation, increased deposition of transactive response DNA-binding protein 43, reduction of
lipid metabolism, accentuated mitochondrial dysfunction, higher susceptibility to
neuroinflammation, reduction of vascular integrity, disruption to insulin and vascular endothelial
growth factor signaling, and disruptions to synaptic plasticity and repair.21 With respect to plasticity,
in particular, it has been suggested that possession of the ε4 allele is associated with higher levels of
synaptic macromolecular turnover, which may facilitate early development but also may stress basic
cellular neuroplasticity mechanisms.8 This would explain the improved early performance at the
expense of a decreased performance during aging.22
Limitations
Even though the current sample size enabled us to investigate differences between ε4 carriers and
ε4 noncarriers, it was not large enough to probe associations of attention and individual APOE
genotypes. These include life-span investigations associated with the dose effect of ε4 (ε3/ε4 vs
ε4/ε4); the role of the AD-protective ε2 variant early in development; and the performance of ε2/ε4
carriers, because the combined effect of possessing both the AD-protective ε2 variant and the
AD-risk ε4 variant is unclear.
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Furthermore, we used 2 different age-appropriate measures to assess attention. Associations
of APOE with different subtypes of attention, as well as different aspects of cognition more broadly,
remain to be investigated to understand whether ε4 is associated with a general early cognitive
advantage.
Conclusions
In this study, APOE ε4 was associated with an attentional advantage early in development and a
disadvantage later in life in individuals with DS, similar to the pattern reported in typical
development. Understanding the differential role of APOE over the life span is an important step
toward targeting interventions based on a better understanding of the risk and protective factors for
life-span development in individuals with DS and in other individuals at risk of AD.
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